Nutriband Inc (NTRB) Stock Analysis

AI analysis of Nutriband Inc (NTRB)

Hold

Nutriband Inc (NTRB) is currently trading at $6.41, which is 56.5% of its 52-week range, indicating it is positioned in the middle of its historical price range. The RSI is at 55.845, suggesting the stock is neither overbought nor oversold. However, the forward P/E ratio is extremely high at 370.37, indicating that the stock may be overvalued based on future earnings expectations. Additionally, the recent earnings report showed an EPS of -0.07, reflecting ongoing losses. While the stock has seen a year-to-date increase of 44.70%, the significant net losses and high valuation metrics present risks. Therefore, it is advisable to hold rather than buy at this time, as the potential for further gains is tempered by these financial concerns.

Valuation Metrics

The current forward P/E ratio for Nutriband Inc (NTRB) is 370.37, compared to its 5-year average forward P/E of 54.60.

Forward P/E

Overvalued

5Y Average P/E

54.60

Current P/E

370.37

Overvalued

213.76

Undervalued

-104.56

Forward EV/EBITDA

Overvalued

5Y Average EV/EBITDA

-6.97

Current EV/EBITDA

0.00

Overvalued

-0.21

Undervalued

-13.74

Forward P/S

Undervalued

5Y Average P/S

10.57

Current P/S

0.00

Overvalued

17.77

Undervalued

3.37

Alphio AI Price Scenarios for NTRB

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NTRB

$8.90

Scenario price

B

Base

Base · 50%NTRB

$6.95

Scenario price

B

Bear

Bear · 25%NTRB

$4.05

Scenario price

NTRB FAQ — answered by Alphio AI

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Nutriband Inc (NTRB) is currently trading at $6.41, which is 56.5% of its 52-week range, indicating it is positioned in the middle of its historical price range. The RSI is at 55.845, suggesting the stock is neither overbought nor oversold. However, the forward P/E ratio is extremely high at 370.37, indicating that the stock may be overvalued based on future earnings expectations. Additionally, the recent earnings report showed an EPS of -0.07, reflecting ongoing losses. While the stock has seen a year-to-date increase of 44.70%, the significant net losses and high valuation metrics present risks. Therefore, it is advisable to hold rather than buy at this time, as the potential for further gains is tempered by these financial concerns.